Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 14/20 | 0.43 |
| ▸ | HTR2B | P41595 | 14/20 | 0.43 |
| ▸ | HTR2A | P28223 | 8/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL981281 | 0.93 | HTR2C (0.45) | HTR6HTR2CHTR2BHTR2A | |
| SCHEMBL21209411 | 0.93 | HTR2C (0.45) | HTR6HTR2CHTR2BHTR2A | |
| SCHEMBL21193054 | 0.93 | HTR2C (0.45) | HTR6HTR2CHTR2BHTR2A | |
| Hydrochloric Acid SCHEMBL3760136 | 0.91 | HTR2C (0.44) | HTR6HTR2CHTR2BHTR2A | |
| SCHEMBL24710914 | 0.88 | HTR6 (0.41) | HTR6HTR2CHTR2BHTR2A | |
| SCHEMBL29145763 | 0.88 | HTR6 (0.41) | HTR6HTR2CHTR2BHTR2A | |
| SCHEMBL28646738 | 0.86 | HTR6 (0.42) | HTR6HTR2CHTR2BHTR2A | |
| SCHEMBL16382755 | 0.86 | HTR6 (0.42) | HTR6HTR2CHTR2BHTR2A | |
| SCHEMBL337591 | 0.85 | HTR2C (0.51) | HTR2CHTR2BHTR2A | |
| SCHEMBL337619 | 0.85 | HTR2C (0.51) | HTR2CHTR2BHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7138395-B2 | Interleukin-1β converting enzyme inhibitors | THE PROCTER & GAMBLE COMPANY (US) | 2006-11-21 | — | — | US | disclosed |
| EP-1511749-A1 | NOVEL INTERLEUKIN-1BETA CONVERTING ENZYME INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 2005-03-09 | — | — | EP | disclosed |
| US-20040014753-A1 | Novel interleukin-1beta converting enzyme inhibitors | THE PROCTER & GAMBLE COMPANY | 2004-01-22 | — | — | US | disclosed |
| WO-2003104231-A1 | NOVEL INTERLEUKIN-1β CONVERTING ENZYME INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 2003-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014753-A1 | Novel interleukin-1beta converting enzyme inhibitors | IL1B, IL1RN, IL1R1 | HTR6 3539/4885HTR2C 2585/4885HTR2B 1273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.